Table 3. .
Clinical outcome
| Characteristics | Control group | Investigation group (Thymalin) | p |
|---|---|---|---|
| Clinical improvement, n, % | 26 (59) | 29 (80.5) | 0.039 |
| Time to clinical improvement, days (M ± SD) | 7.61 ± 0.93 | 8.63 ± 0.68 | 0.41 |
| CT scan follow-up at day 14 | |||
| Improvement, n, % | 10 (22.7) | 11 (30.5) | 0.43 |
| Stable, n, % | 17 (38.6) | 16 (44.4) | 0.61 |
| Progression, n, % | 17 (38.6) | 9 (25) | 0.19 |
| Mortality | |||
| In hospital mortality, n, % | 18 (40.9) | 7 (19.4) | 0.039 |
| Time from randomization to death, days (M ± SD) | 7.22 ± 0.65 | 11.2 ± 0.49 | 0.005 |
| Laboratory recovery | |||
| Lymphocyte recovery, n, % | 19 (43.18) | 24 (66.6) | 0.037 |
| Time to lymphocyte recovery, days (M ± SD) | 10.78 ± 0.53 | 7.36 ± 0.56 | 0.002 |
| COVID-19 clearance time among survivors, days (M ± SD) | 18.27 ± 0.38 | 19.75 ± 0.47 | 0.31 |
The values of the significance level p are highlighted in bold, indicating significant differences between the groups.